A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine PlatformAnna Malczyk, Michael D. Mühlebach|Journal of Virology|2015Cited by 124
Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2 /neu or EpCAM as target receptorsJan R.H. Hanauer, Michael D. Mühlebach, Dennis Riehl et al.|Molecular Therapy — Oncolytics|2016Cited by 22